Parkinson's drooling drug shows promise in new trial
NCT ID NCT06319118
First seen Mar 28, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tested a tablet called dihydroergotine mesylate extended-release to see if it can reduce drooling in people with Parkinson's disease. 120 patients took either the study drug or a placebo for 12 weeks, along with their usual treatments. The goal was to measure changes in saliva weight and check for any effects on thinking skills.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVATION IN PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Arilliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China
Conditions
Explore the condition pages connected to this study.